Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Sep;79(7):686-691.
doi: 10.1007/s00393-020-00878-0. Epub 2020 Aug 26.

[SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]

[Article in German]
J Leipe  1   2 , B F Hoyer  3 , C Iking-Konert  4 , H Schulze-Koops  5 , C Specker  6 , K Krüger  7
Affiliations
Comparative Study

[SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]

[Article in German]
J Leipe et al. Z Rheumatol. 2020 Sep.

Abstract
in English, German

The recommendations of the German Society of Rheumatology (DGRh) update, which update and expand the guidance on the management of patients with inflammatory rheumatic diseases in view of SARS-CoV‑2 created at the beginning of the COVID-19 pandemic, correspond in many points with the recommendations for action of the American (ACR) and European (EULAR) societies, but also differ in some points. Therefore, this article discusses the core recommendations of the DGRh update on the prevention of SARS-CoV-2/COVID-19, the risk assessment for inflammatory rheumatic diseases and the use of antirheumatic treatments in the context and in comparison to the ACR and EULAR recommendations, and provides an overview of the risk assessment of individual antirheumatic drugs.

Die Empfehlungen des Deutschen Gesellschaft für Rheumatologie(DGRh)-Updates – welches die zu Beginn der COVID-19-Pandemie erstellte Hilfestellung zum Management von Patienten mit entzündlich rheumatischen Erkrankungen angesichts der Bedrohung durch SARS-CoV‑2 aktualisiert und erweitert – stimmen in vielen Punkten mit den Handlungsempfehlungen der amerikanischen (ACR) und europäischen Fachgesellschaften (EULAR) überein, unterscheiden sich aber auch in einigen Punkten. In diesem Artikel sollen daher Kernempfehlungen des DGRh-Updates zu den Themen Prävention von SARS-CoV-2/COVID-19, Risikoeinschätzung bei ERE sowie der Umgang mit antirheumatischen Therapien im Kontext bzw. im Vergleich zu den ACR- und EULAR-Empfehlungen diskutiert und eine Übersicht zur Risikobeurteilung einzelner antirheumatischer Medikamente gegeben werden.

Keywords: COVID-19; DMARD; Inflammatory rheumatic diseases; Management; Recommendations.

PubMed Disclaimer

References

    1. Aries P, Iking-Konert C. No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany) Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-218400. - DOI - PubMed
    1. Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2020 doi: 10.1016/j.pulmoe.2020.07.003. - DOI - PMC - PubMed
    1. D’silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-217888. - DOI - PMC - PubMed
    1. Damiani G, Pacifico A, Bragazzi NL, et al. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020 doi: 10.1111/dth.13475. - DOI - PMC - PubMed
    1. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859–866. doi: 10.1136/annrheumdis-2020-217871. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources